Company news
Zhejiang Huahai Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Disclosure of the 2025 Annual Report by the Holding Subsidiary, Changxing Pharmaceutical Co., Ltd.
April 28, 2026
Announcement on the Return of Raised Funds
April 24, 2026
Announcement on Holding Open Day Activities for Investor
April 21, 2026
Announcement on Resolutions of the 10th Extraordinary Meeting of the 9th Board of Directors
April 17, 2026
Earnings Preannouncement for Q1 2026
April 14, 2026
Indicative Announcement on Expected Trigger of Downward Revision for the Conversion Price of ""Huahai Convertible Bonds"
April 10, 2026
Announcement on Conversion Result of Convertible Corporate Bonds and Share Changes
April 1, 2026
Announcement on Resolutions of the 9th Extraordinary Meeting of the 9th Board of Directors
March 27, 2026
Announcement on Resolutions of the 8th Extraordinary Meeting of the 9th Board of Directors
March 20, 2026
Announcement on Maturity of Partial Idle Raised Funds Used for Cash Management
March 19, 2026
Announcement on Subsidiary HB0025 Injection Initiating Endometrial Cancer Phase III Clinical Trial
March 18, 2026
Announcement on Obtaining the U.S. FDA Approval for the Product Gabapentin Capsules
March 10, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
March 9, 2026
Announcement on Progress in Legal Proceedings Involving the Company and Its Subsidiaries
February 27, 2026
Announcement on Obtaining the Notice on Approval of Drug Supplement Application
February 3, 2026
Announcement on Expected Decrease in Performance for 2025
January 26, 2026
On-Site Inspection Report of Zheshang Securities Co., Ltd. on Continuous Supervision over ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. in 2025
January 5, 2026
Announcement on Release of Pledge of Partial Equity of Shareholder
December 31, 2025
Announcement on Optional Repurchase Results of "Huahai Convertible Bonds"
December 30, 2025
Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial
December 26, 2025
Announcement on Progress in Drug Clinical Trials by Subsidiary
November 19, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 10, 2025
Announcement on the Subsidiary Passing On-site Inspection by FDA
November 6, 2025
Announcement on Not Revising Downward the Conversion Price of ""HUAHAI Convertible Bonds"
November 5, 2025
Report for Q3 2025
October 30, 2025
Announcement on Products Being Prospective Winners in the 11th National Centralized Drug Procurement
October 28, 2025